New drug TAK-279 targets rare, severe psoriasis in phase 3 trial
NCT ID NCT06323356
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-label, meaning everyone knows they are getting the active treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-279 (a drug taken by mouth)
What this could lead to
If it works, this could provide a new treatment option for people with rare, severe forms of psoriasis that are hard to control.
What could go wrong
This is a small, open-label study with only 18 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
-
Fukuoka University Hospital
Fukuoka, Japan
-
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu, Fukuoka, Japan
-
Isesaki Municipal Hospital
Isesaki, Gunma, Japan
-
Juntendo University Urayasu Hospital
Urayasu, Chiba, Japan
-
Kansai Medical University Hospital
Hirakata, Osaka, Japan
-
Kimitsu Chuo Hospital
Kisarazu, Chiba, Japan
-
Kobe University Hospital
Kobe, Hyōgo, Japan
-
Mie University Hospital
Tsu, Mie-ken, Japan
-
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
-
Nippon Life Hospital
Osaka, Japan
-
Okayama University Hospital
Okayama, Japan
-
Osaka Metropolitan University Hospital
Osaka, Japan
-
Saitama Medical University Hospital
Iruma, Saitama, Japan
-
St.Luke's International Hospital
Chūō, Tokyo, Japan
-
Teikyo University Hospital
Itabashi-ku, Tokyo, Japan
-
The Jikei University Hospital
Minato-ku, Tokyo, Japan
-
Tokai University Hospital
Isehara, Kanagawa, Japan
-
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
-
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Japan